Related Experiment Video
Updated: Jun 19, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[What's new in the treatment of hepatitis B infection?]
1Service de gastroentérologie et d'hépatologie, Pr Francesco Negro Service de pathologie clinique, HUG, 1211 Geneve 14. Francesco.Negro@hcuge.ch
Abstract:
Although the number of available antiviral drugs for hepatitis B infection (VHB) today is higher than ever, treatment of chronic VHB infection is still often managed by specialists because of the complex natural history of this viral infection and of the risk of selecting viral strains that are resistant to therapy. Different clinical and virological aspects need to be considered to establish a correct indication for therapy. Once antiviral therapy has been started, patients need close monitoring to guarantee adequate compliance and to detect promptly the selection of viral variants resisting to therapy.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Retrovirus Life Cycles
